CURRICULUM VITAE

Nome: Alfredo Nicosia

Nazionalità: Italiana

ISTRUZIONE

1976	Maturità Scientifica (votazione 60/60)
1977-1983	Facoltà di Chimica all'Università di Roma
1983	Laurea in Chimica (votazione: 110/110 con lode) Titolo della tesi: *Induction of synchronous duplication of E.coli K12 by a lig⁻ mutant of bacteriophage Mu*

ESPERIENZA PRE-DOTTORATO

1980-1983	National research Council, Centro Acidi Nucleici (Rome) Regulation group. Progetto: *Study of the effects induced by a lig⁻ mutant of bacteriophage Mu on E. coli DNA replication.* Supervisori: Prof. E. Calef, Dr. L. Paolozzi

ESPERIENZA POST-DOTTORATO

1983-1984	Postdoc Istituto Superiore di Sanità (Rome), Dipartimento di Microbiologia. Progetto: Structure and function of the genes encoding for Cholera toxin. Direttore di Ricerca: Dr. M.L. Gennaro.
1985-1986	Postdoc Centro di Ricerca SCLAVO (Siena), Dipartimento di Biologia Molecolare. Progetto: Structure, function and regulation of the genes encoding for Pertussis toxin. Direttore di Ricerca: Dr. R. Rappuoli.
1986-1988	Postdoc Laboratorio di Biologia Molecolare Europea (Heidelberg), Gene Structure and Regulation Programme. Progetto: Tissue-specific expression of liver genes. Direttore di Ricerca: Prof. R. Cortese.
1988-1990	Staff Scientist Laboratorio di Biologica Molecolare Europea (Heidelberg), Gene Structure and Regulation Programme.
1990-2007	Istituto di Ricerche di Biologia Molecolare P. Angeletti (Pomezia-Rome), Dipartimento di Biologia Molecolare e Cellulare

1990-1998	Group Leader
1998-1999	Research Fellow
1999-2002	Senior Investigator
2002-2004	Director
2004-2007	Senior Director

2007-2013	Capo Scientifico, Okairos (Rome-Naples)
Mag 2013 – Genn 2014	Consulente per GlaxoSmithKline
2014-presente	Presidente, Okairos (oggi ReiThera)
2014-presente	Membro del Consiglio Scientifico Consultivo del Jenner Institute, Oxford
2014-presente	Presidente, Nouscom Srl
Mag 2017-presente	Presidente Officer, Keires AG
Giug 2017-presente	Presidente, Nouscom AG

ESPERIENZA ACCADEMICA

2002-2006	Lecturer, International First Level Degree, Università di Perugia, "Job Creation Oriented Biotechnology"
2010-presente:	Professore Ordinario di Biologia Molecolare, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II.

INTERESSI SCIENTIFICI

- Meccanismo di integrazione del genoma del batteriogafo nella cellula ospite.
- Struttura, funzione e regolazione delle tossine batteriche.
- Regolazione trascrizionale tessuto specifica in cellule di mammifero; relazioni di struttura e funzione di fattori trascrizionali eucariotici.
- Phage display di peptide e protein dei faggi M13 e Lambda; studio di antigeni patologia specifici attraverso il phage displayed peptide.
- Genomica funzionale: identificazione di protein coinvolte nelle interazioni proteina/proteina e proteina/DNA.
- Antibody phage display; identificazione e caratterizzazione di anticorpi da librerie phage displayed scFv.
- Generazione di anticorpi monoclonali per vaccini genetici.
- Anticorpi terapeutici contro agenti infettivi e cancro.
- Meccanismi della risposta immunitaria B e T-cell mediate all'infezione virale; antigen delivery attraverso vettori virali ricombinanti e DNA nudo.
- Vaccini genetici contro malattie infettive (HIV, HCV, Malaria, Ebola, RSV, Influenza) e cancro.

LISTA DELLE PUBBLICAZIONI

1 Nicosia A., Franzini C., Ratti G., Perugini M., Casagli M.C., Borri M.G., Antoni G., Almoni, M., Neri P., Rappuoli R.
Cloning of the genes coding for Pertussis Toxin
Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene. Falamagne et al. (Eds.) 289-290 (1986)

2 Nicosia A., Perugini M., Franzini C., Casagli M.C., Borri M.G., Antoni G., Almoni M., Neri P., Ratti G., Rappuoli R.
Cloning and sequencing of the pertussis toxin genes: Operon structure and gene duplication
Proc. Natl. Acad. Sci. 83, 4631-4635 (1986)

3 Rappuoli R., Nicosia A., Bartoloni A., Arico' B., Gross R., Perugini M.
Application of recombinant DNA technology for the production of a third generation pertussis vaccine
Proc. 4th European Congress on Biotechnology, Elsevier Science Publishers B.V. 491-496 (1987)

4 Nicosia A. Bartoloni A. Perugini M., Rappuoli R.
Expression and immunological properties of the five subunits of pertussis toxin
Infection and Immunity 55, 963-967 (1987)

5 Rappuoli R., Nicosia A., Arico' B., Bartoloni A., Perugini M., Gross R.
Toward a recombinant DNA vaccine against pertussis
Biotechnology in Clinical Medicine, Raven Press, Ltd., New York 205-210 (1987)

6 Nicosia A., Rappuoli R.
Promoter of the pertussis toxin operon and production of pertussis toxin
Journal of Bacteriology 169, 2843-2846 (1987)

7 Monaci P., Nicosia A., Cortese R.
Two different liver-specific factors stimulate in vitro transcription from the human alpha-1 antitrypsin promoter
EMBO J. 7, 2075-2087 (1988)

8 Monaci P., Nicosia A., Cortese R.
Cis-elements and trans-acting factors involved in the tissue-specific expression of the human alpha-1 antitrypsin gene
in "Tissue-specific gene expression" pp 149-164 (1989)
Renkawitz eds.,VCH Verlagsgesellschaft, Weinheim, Deutschland

9 Frain M., Swart G., Monaci P., Nicosia A., Staempfli S., Frank R., Cortese R.
The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain
Cell 59, 145-157 (1989)

10 Paolozzi L., Nicosia A., Liebart J.C., Ghelardini P.
Synchronous division induced in Escherichia coli K12 by gemts mutants of phage Mu
Mol. Gen. Genet. 218, 13-17 (1989)

11 Toniatti C., Demartis A., Monaci P., Nicosia A., Ciliberto G.
Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites
EMBO J. 9, 4467-4475 (1990)

12 Nicosia A., Monaci P., Tomei L., DeFrancesco R., Nuzzo M., Stunnenberg H., Cortese R.
A myosin-like dimerization helix and an extra-large homeodomain are essential elements of the tripartite DNA binding structure of LFB1

Cell 61, 1225-1236 (1990)

13 Yamada K., Noguchi T., Matsuda T., Takenaka M., Monaci P., Nicosia A., Tanaka T.
Identification and characterization of hepatocyte-specific regulatory regions of the rat pyruvate kinase L gene
The Journal of Biological Chemistry 265, 19885-19891 (1990)

14 Imai E., Noguchi T., Takenaka M., Yamada K., Matsuda T., Monaci P, Nicosia A., Tanaka T.
Alteration in L-type pyruvate kinase gene expression is not associated with the LFB1 mRNA level.
Biochem. & Biophys. Res. Comm. 176, 1074-1078 (1991)

15 De Simone V., De Magistris L., Lazzaro D., Gerstner J., Monaci P., Nicosia A., Cortese R.
LFB3, a heterodimer-forming homeoprotein of the LFB1 family, is expressed in specialized epithelia
EMBO J. 10, 1435-1443 (1991)

16 Papazafiri P., Ogami K., Ramji DP., Nicosia A., Monaci P., Cladaras C., Zannis V.
Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene: positive and negative regulators bind to overlapping sites
The Journal of Biological Chemistry 266, 5790-5797 (1991)

17 Nicosia A. Tafi R., Monaci P.
Trans-dominant inhibition of transcription activator LFB1
Nucleic Acid Research 20, 5321-5328 (1992)

18 Monaci P., De Francesco R., Tomei L., Nicosia A.
LFB1: a transcriptional activator of hepatocyte-specific genes
In 'Hepatic transport and Bile secretion: physiology and pathophysiology", pp 145-153 (1993)
Tavoloni N. and Berk PD eds, Raven press, NY

19 Toniatti C., Monaci P., Nicosia A., Cortese R., Ciliberto G.
A bipartite activation domain is responsible for the activity of transcription factor HNF1/LFB1 in cells of hepatic and non-hepatic origin
DNA and Cell Biology 12, 199-208 (1993)

20 Ciliberto G., Colantuoni V., De Francesco R., De Simone V., Monaci P., Nicosia A., Ramji D.P., Toniatti C. and Cortese R.
Transcriptional control of gene expression in hepatic cells
In "Research in gene expression series" Karin M. ed, Birkauser Boston Inc., chapter 7, 162-242 (1993)

21 Ceska TA., Lamers M., Monaci P., Nicosia A., Cortese R., Suck D.
The X-ray structure of an atypical homeodomain present in the rat liver transcription factor LFB1/HNF1 and implications for DNA binding
EMBO J. 12, 1805-1810 (1993)

22 Tramontano A., Pizzi E., Felici F., Luzzago A., Nicosia A., Cortese R.
A database system for handling phage library-derived sequences
Gene 128, 143-144 (1993)

23 Folgori A., Tafi R., Meola A., Nuzzo M., Motti C., Galfre' G., Felici F., Cortese R., Monaci P., Nicosia A.
Selection of epitopes from phage displayed peptide libraries using human sera: a new tool for the identification of antigenic and immunogenic mimotopes
Proc. 6th European Workshop on Bacterial Protein Toxins, suppl. 24 Gustav Fisher, Stuttgart, Jena, New York (1994)

24 Folgori A., Tafi R., Meola A., Felici F., Galfré G., Cortese R., Monaci P., Nicosia A.
A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera
EMBO J. 13, 2236-2243 (1994)

25 Cortese R., Felici F., Galfre' G., Luzzago A., Monaci P., Nicosia, A.
Epitope discovery using peptide libraries displayed on phage
Trends Biotechnol. 12, 262-267 (1994)

26 Motti C., Nuzzo M., Meola A., Galfre' G., Felici F., Cortese R., Nicosia A., Monaci P.
Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library
Gene 146, 191-198 (1994)

27 Dente L., Cesareni G., Micheli G., Felici F., Folgori A., Luzzago A., Monaci P., Nicosia A., Delmastro P.
Monoclonal antibodies that recognise filamentous phage: tools for phage display technology
Gene 148, 7-13 (1994)

28 Felici F., Luzzago A., Monaci P., Nicosia A., Sollazzo M., Traboni C.
Peptide and protein display on the surface of filamentous bacteriophage
In Biotechnology Annual Review, vol. 1, pp. 149-183 (1995)
M. Raafat El-Gewely ed., Elsevier Science B.V., Amsterdam, The Netherland

29 Cortese R., Monaci P., Nicosia A., Luzzago A., Felici F., Galfre' G., Pessi A., Tramontano A., Sollazzo M.
Identification of biologically active peptides using random libraries displayed on phage
Current Opinions in Biotechnology 6, 73-80 (1995)

30 Cesareni G., Castagnoli L., Dente L., Iannolo G., Vetriani C., Felici F., Luzzago A., Monaci P., Nicosia, A., Cortese R.
Construction and utilization of peptide libraries displayed by filamentous bacteriophage.
In "Immunological recognition of peptides in medicine and biology", pp. 43-59 (1995)
N.D. Zegers, W.J.A. Boersma and E. Claassen, CRC Press

31 Meola A., Delmastro P., Monaci P., Luzzago A., Nicosia A., Felici F., Cortese R., Galfre', G.
Derivation of vaccines from mimotopes. Immunological properties of human hepatitis B surface antigen mimotopes displayed on filamentous phage
Journal of Immunology, 154, 3162-3172 (1995)

32 Monaci P., Nuzzo M., Stampfli S., Tollervey D., DeSimone V., Nicosia A.
A complex interplay of positive and negative elements is responsible for the different transcriptional activity of liver NF1 variants
Molecular Biology Reports 21, 147-158 (1995)

33 Nicosia A., Monaci P., Luzzago A., Galfre' G., Felici F., Prezzi C., Mennuni C., Meola A., Mecchia M., Cortese R.
Discovery of disease-specific mimotopes by screening phage libraries with human serum samples
In" Combinatorial libraries: synthesis, screening and application potential", pp. 145-157 (1996), Cortese R. ed., W. de Gruyter, Berlin

34 Nicosia A., Monaci P.
Alpha1-antitrypsin gene expression in hepatocytes
In "Alpha1-antitrypsin deficiency" pp. 143-162 (1996). Crystal R.G., Hubbard R.C., Trapnell B.C. eds., Dekker M., N.Y.

35 Galfre' G., Monaci P., Nicosia A., Luzzago A., Felici F., Cortese R.
Immunization with phage-displayed mimotopes
Methods in Enzymology 267, 109-115 (1996)

36 Felici F., Galfre' G., Luzzago A., Monaci P., Nicosia A., Cortese R.
Phage-displayed peptides as tools for the characterization of human sera
Methods in Enzymology 267, 116-129 (1996)

37 Bartoli F., Nuzzo M., Pezzanera M., Nicosia A., Monaci P.
Rapid Protocol for template preparation of large numbers of clones

Biotechniques 20, 554-558 (1996)

38 Prezzi C., Nuzzo M., Meola A., Delmastro P., Galfre' G., Cortese R., Nicosia A., Monaci P.
Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients
J. Immunol. 156, 4504-4513 (1996)

39 Cortese R., Monaci P., Luzzago A., Santini C., Bartoli F., Cortese I., Fortugno P., Galfre' G., Nicosia A., Felici F.
Selection of biologically active peptides by phage display of random peptide libraries
Current Opinions in Biotechnology 7, 616-621 (1996)

40 Mecchia M., Casato M., Tafi R., Filocamo G., Bonomo L., Fiorilli M., Cortese R., Migliaccio G., Nicosia A.
Non rheumatoid IgM in HCV-associated type II cryoglobulinemia recognise mimotopes of the CD4-like LAG-3 protein
J. Immunol. 157, 3727-3736 (1996)

41 Cortese I., Tafi R., Grimaldi LM., Martino, G., Nicosia, A., Cortese R.
Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis using phage libraries
Proc. Natl. Acad. Sci., 93, 11063-11067 (1996)

42 Cerino A., Bissolati M., Cividini A., Nicosia A., Esumi M., Hayashi N., Mizuno K., Slobbe R., Oudshoorn P., Silini E., Asti M., Mondelli MU.
Antibody responses to the hepatitis C virus E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects
Journal of Medical Virology, 51, 1-5 (1997)

43 Tafi R., Bandi R., Prezzi, C., Mondelli MU., Cortese R., Monaci P., Nicosia, A.
Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides
Biological Chemistry, 378(6), 495-502 (1997)

44 Folgori A., Luzzago A., Monaci P., Nicosia A., Cortese R., Felici F.
Identification of disease-specific epitopes
In "Methods in Molecular Biology, Combinatorial peptide libraries
S. Cabilly; Humana Press, Totowa, NJ, USA, 87, 195-208 (1998)

45 Cortese I., Capone S., Tafi R., Grimaldi LM., Nicosia A., Cortese R.
Identification of peptides binding to IgG in the CSF of multiple sclerosis patients
Multiple Sclerosis, 4(1), 31-36 (1998)

46 Cortese I., Capone S., Luchetti S., Grimaldi LM., Nicosia A., Cortese R.
CSF-enriched antibodies do not share specificities among MS patients
Multiple Sclerosis, 4(3), 118-123 (1998)

47 Puntoriero G., Meola A., Lahm A., Zucchelli S., Ercole BB., Tafi R., Pezzanera M., Mondelli MU., Cortese R., Tramontano A., Galfre' G., Nicosia A.
Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants
EMBO J., 17(13), 3521-3533 (1998)

48 Santini C., Brennan D., Mennuni C., Hoess RH., Nicosia A., Cortese R., Luzzago A.
Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda
J. Mol. Biol., 282(1), 125-135 (1998)

49 Frasca L., Del Porto P., Tuosto L., Marinari B., Scottà C., Carbonari M., Nicosia A., Piccolella E.
Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells
J. Immunol., 163(2), 650-658 (1999)

50 Mondelli MU., Cerino A., Lisa A., Brambilla S., Segagni L., Cividini A., Bissolati M., Missale G., Bellati G., Meola A., Bruniercole B., Nicosia A., Galfre' G., Silini E.
Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation
Hepatology 30(2), 537-545 (1999)

51 Santi E., Capone S., Mennuni C., Lahm A., Tramontano A., Luzzago A., Nicosia A.
Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics
J. Mol. Biol., 296(2), 497-508 (2000)

52 Yagnik A.T., Lahm A., Meola A., Roccasecca RM., Ercole BB., Nicosia A.,Tramontano A.
A model for the hepatitis C virus envelope glycoprotein E2.
Proteins, 40(3), 355-66 (2000).

53 Meola A., Sbardellati A., Ercole BB., Cerretani M., Pezzanera M., Ceccacci A., Vitelli A., Levy S, Nicosia A., Traboni C., McKeating J., Scarselli E.
Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.
J Virol., 74(13), 5933-8 (2000).

54 Del Porto P., Puntoriero G., Scottà C., Nicosia A., Piccolella E.
High prevalence of hypervariable region 1-specific and -cross-reactive CD4(+) T cells in HCV-infected individuals responsive to IFN-alpha treatment.
Virology. 269(2), 313-24 (2000).

55 Higginbottom A., Quinn E.R., Kuo C.C., Flint M., Wilson LH., Bianchi E., Nicosia A., Monk P.N., McKeating JA, Levy S.
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.
J Virol., 74(8), 3642-9 (2000).

56 Zucchelli S., Capone S., Fattori E., Folgori A., Di Marco A., Casimiro D., Simon A.J, Laufer R., La Monica N., Cortese R., Nicosia A.
Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.
J Virol., 74(24), 11598-607 (2000).

57 Cortese I., Capone S., Luchetti S., Cortese R., Nicosia A.
Cross-reactive phage-displayed mimotopes lead to the discovery of mimicry between HSV-1 and a brain-specific protein.
J. Neuroimmunology, 113(1), 119-128 (2001).

58 Zucchelli S., Roccasecca R., Meola A., Ercole BB., Tafi R, Dubuisson J., Galfre' G., Cortese R., Nicosia A.
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences induce cross-reactive antibody response by genetic immunization.
Hepatology, 33, 692-703 (2001).

59 Roccasecca R., Folgori A., Ercole BB., Puntoriero G., Lahm A., Zucchelli S., Tafi R., Pezzanera M., Galfre' G., Tramontano A, Mondelli MU., Pessi A, Nicosia A., Cortese R., Meola A.
Mimotopes of the hypervariable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes.
Molecular Immunology, 38(6), 485-92 (2001).

60 Cerino A., Meola A., Segagni L., Furione M., Marciano S., Triyatni M., Liang JT., Nicosia A., Mondelli MU.
Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles.
J. Immunol., 167(7), 3878-86 (2001).

61 Mondelli MU., Cerino A., Segagni L., Meola A., Cividini A., Silini E., Nicosia A.

Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?
Antiviral Research, 52(2), 153-9 (2001).

62 Roccasecca R., Folgori A., Ercole BB., Puntoriero G., Lahm A., Zucchelli S., Tafi R., Pezzanera M., Galfre' G., Tramontano A., Mondelli MU., Pessi A., Nicosia A, Cortese R.,Meola A.
Induction of cross-reactive humoral immune response by immunization with mimotopes of the hypervariable region 1 of the hepatitis C virus.
Int Rev Immunol., 20(2), 289-300 (2001)

63 Ansuini H., Cicchini C., Nicosia A., Tripodi M., Cortese R., Luzzago A.
Biotin-tagged cDNA expression libraries displayed on lambda phage: a new tool for the selection of natural protein ligand
Nucleic Acids Res., 30(15):e78 (2002)

64 Cicchini C., Ansuini H., Amicone L., Alonzi T., Nicosia A, Cortese R., Tripodi M., Luzzago A.
Searching for DNA-protein interactions by lambda phage display.
J. Mol. Biol., 322(4), 697- 706 (2002).

65 Scarselli E., Ansuini H., Cerino R., Roccasecca RM., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A.
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.
EMBO J., 21, 5017-5025 (2002)

66 Roccasecca R., Ansuini H., Vitelli A., Meola A., Scarselli E., Acali S., Pezzanera M., Ercole BB, McKeating J., Yagnik A., Lahm A., Tramontano A, Cortese R., Nicosia A.
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain-specific and is modulated by a complex interplay between the hypervariable regions 1 and 2.
J. Virol., 77(3), 1856-67 (2003)

67 Mondelli MU., Cerino A., Meola A., Nicosia A
Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses
Journal of Biosciences, 28(3), 305-310 (2003)

68 Frasca L., Scottà C., Del Porto P., Nicosia A, Pasquazzi C., Versace I,. Masci AM,. Racioppi L., Piccolella E.
Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes.
Hepatology, 38(3), 653-663 (2003)

69 Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J., Pascale S., Scarselli E., Cortese R., Nicosia A., Cosset FL.
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
J Biol Chem., 278(43), 41624-30 (2003)

70 Spada E., Mele A., Berton A., Ruggeri L., Ferrigno L., Garbuglia AR., Perrone MP., Girelli G., Del Porto P., Piccolella E., Mondelli MU., Amoroso P., Cortese R., Nicosia A., Vitelli A., Folgori A.
Multi-specific T-cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneousus clearance
Gut, 53(11), 1673-81 (2004)

71 Catalucci D., Sporeno E., Cirillo A., Ciliberto G., Cortese R., Nicosia A., Colloca S.
An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent delta E1-E2-E3-E4- Ad5 vectors
J Virology, 79(10), 6400-9 (2005)

72 Al-Sherbiny M., Osman A., Mohamed N., Shata MT., Abdel-Aziz F., Abdel-Hamid M., Abdelwahab SF., Mikhail N., Stoszek S., Ruggeri L., Folgori A., Nicosia A., Prince AM., Strickland GT.
Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion
American Journal of Tropical Medicine and Hygiene, 73(1), 44-49 (2005)

73 Zampaglione I., Arcuri M., Cappelletti M., Ciliberto G., Perretta G., Nicosia A., La Monica N., Fattori E.
In vivo DNA gene electro-transfer: a systematic analysis of different electrical parameters.
J Gene Med., 7(11), 1475-81 (2005)

74 Guglietta S., Garbuglia AR., Pacciani V., Scottà C., Perrone MP., Laurenti L., Spada E., Mele A., Capobianchi MR., Taliani G., Folgori A., Vitelli A., Ruggeri L., Nicosia A., Piccolella E., Del Porto P.
Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection.
Eur J Immunol., 35(9), 2627-2637 (2005)

75 Persico M., Perrotta S., Persico E., Terracciano L., Folgori A., Ruggeri L., Nicosia A., Vecchione R., Mura VL, Masarone M. and Torella R..
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at ten years
J. of Viral Hepatitis, 13(5), 290-6 (2005)

76 Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole BB, Pezzanera M., Tafi R., Arcuri M., Fattori E., Lahm A., Luzzago L., Vitelli A., Colloca S., Cortese R., Nicosia A.
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees
Nature Medicine, 12(2), 190-7 (2006)

77 Folgori A., Spada E., Pezzanera M., Ruggeri L., Mele A., Garbuglia AR., Perrone MP, Del Porto P., Piccolella E., Cortese R., Nicosia A., Vitelli A.
Early impairment of HCV-specific T-cell proliferation during acute infection leads to failure of viral clearance
Gut, 55(7), 1012-9 (2006)

78 Capone S., Meola A., Ercole B.B., Vitelli A., Pezzanera M., Davies ME, Tafi R., Santini C., Luzzago A., Fu TM., Bett A., Colloca S., Cortese R., Nicosia A., Folgori A.
A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes pre-existing anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
Journal of Virology, 80(4), 1688-99 (2006)

79 Fattori E., Zampaglione I., Capone S., Finnefrock AC., Simon AJ., Casimiro DR., Kath GS., Shiver J., Tang A., Folgori A., La Monica N., Ciliberto G., Cortese R., Nicosia A.
Genetic vaccination by gene electro-transfer in non-human primates
J. Drug Del Sci Tech, 16(1), 85-89 (2006)

80 Fattori E., Zampaglione I., Arcuri M., Meola A., Ercole BB., Cirillo A., Folgori A., Bett A., Cappelletti M., Sporeno E., Cortese R., Nicosia A., Colloca S.
Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes
Gene Ther., 13(14), 1088-96 (2006)

81 Capone S., Zampaglione I., Vitelli, A., Pezzanera, M., Kirstead L., Burns J., Ruggeri L., Arcuri M., Cappelletti M., Meola A., Ercole B.B., Tafi R., Santini C., Luzzago A., Fu TM., Colloca S., Ciliberto G., Cortese, R., Nicosia A., Fattori E., Folgori A.
Modulation of the immune response induced by Gene Electro Transfer of a hepatitis C virus DNA vaccine in non human primates

Journal of Immunology, 177(10), 7462-71 (2006)

82 Catanese MT., Graziani R., von Hahn T., Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A.
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
J Virol., 81(15), 8063-71 (2007)

83 Scottà C., Garbuglia AR., Ruggeri L., Spada E., Laurenti L., Perrone MP., Girelli G., Mele A., Capobianchi MR., Folgori A., Nicosia A., Del Porto P., Piccolella E.; on behalf of the Acute Hepatitis C Italian Study Group.
Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region during acute HCV infection.
J Hepatol., 48(2), 216-28 (2008)

84 Monaci P., Luzzago A., Santini C., De Pra A., Arcuri M., Magistri M., Bellini A., Ansuini A., Ambrosio A., Ammendola V., Bigotti MG., Cirillo A., Nuzzo M. , Nasti AA., Neuner P., Orsatti L., Pezzanera M., Sbardellati A., Silvestre G., Uva .P, Viti V., Barbato G., Colloca S., Demartis A., De Rinaldis E., Giampaoli S., Lahm A., Palombo F., Talamo F., Vitelli A., Nicosia A., Cortese R.
Differential Screening of phage-ab libraries by oligonucleotide microarray technology
Plos One, 3(1) e1508 (2008)

85 Strickland T., El-Kamary S., Klenerman P., Nicosia A.
Hepatitis C Vaccine: Demand and Supply.
Lancet Infectious Diseases., 21(3), 379-386 (2008)

86 Arcuri M., Cappelletti M., Zampagliene I., Aurisicchio L., Nicosia, A., Ciliberto G., Fattori E.
Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination.
The Journal of Gene Medicine, (2008) 10(9):1048-54

87 Shin EC., Capone S., Cortese R., Colloca S., Nicosia A., Folgori A., Rehermann B.
The Kinetics of Hepatitis C Virus-Specific CD8 T cell Responses in the Blood Mirrors Those in the Liver in Acute Hepatitis C Virus Infection.
J Virol., (2008) 82(19):9782-8

88 Inchauspè G., Honnet G., Bonnefoy JY., Nicosia A., Strickland GT.
Hepatitis C Vaccine: supply and demand.
Lancet Infect Dis. 2008 Dec;8(12):739-40

89 Riva E., Maggi F., Abbruzzese F., Bellomi F., Giannelli G., Picardi A., Scagnolari C., Folgori A., Spada E., Piccolella E., Dianzani F., Antonelli G., **Acute Hepatitis C Italian Study Group.**
Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.
Med Microbiol Immunol. 2009 Feb;198(1):13-8. Epub 2008 Aug 12

90 Peruzzi D., Dharmapuri S., Cirillo A., Bruni BE, Nicosia A., Cortese R., Colloca S., Ciliberto G., La Monica N., Aurisicchio L.
A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.
Vaccine, 2009 27(9):1293-300

91 Dudareva M., Andrews L., Gilbert SC., Bejon P., Marsh K., Mwacharo J., Kai O., Nicosia A., Hill AV.
Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
Vaccine, 2009 27(27):3501-4

92 Catanese MT., Ansuini H., Graziani R., Huby T., Moreau M., Ball JK., Paonessa G., Rice CM., Cortese R., Vitelli A., Nicosia A.
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

J Virol. 2010 84(1):34-43

93 Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert SC., Nicosia A., Colloca S., Cortese R., Hill AV.
Prime-boost immunization with adenoviral and MVA vectors enhances the durability and polyfunctionality of protective malaria CD8+ T cell responses.
Infect Immun. 2010 78(1):145-53

94 Ansuini H., Meola A., Gunes Z., Paradisi V., Pezzanera M., Acali S., Santini C., Luzzago A., Mori F., Lazzaro D., Ciliberto G., Nicosia A., LaMonica N., Vitelli A.
Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.
J Oncol. 2009;2009:951917. Epub 2010 Jan 14

95 Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., Nicosia A., Folgori A., Colloca S, Cortese R, Gilbert S.C., Draper SJ.
Prime-boost vectored malaria vaccines: Progress and prospects.
Hum Vaccin. 2010 Jan;6(1):78-83

96 Marra E., Uva P., Viti V., Simonelli V., Dogliotti E., DeRinaldis E., Lahm A., LaMonica N., Nicosia A., Ciliberto G., Palombo F.
Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signalling pathways.
BMC Cancer 2010 Apr 7;10:129

97 Rosario M., Bridgeman A., Quakkelaar ED., Quigley MF., Hill BJ., Knudsen ML., Ammendola V., Ljundberg K., Borthwick N., Im E.J., McMichael A.J., Drijfhout J.W., Genaway H.Y., Venturi V., Douek D.C., Colloca S., Liljestrom P., Nicosia A., Price DA., Hanke T.
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
Eur J Immunol 2010 Jul;40(7):1973-84

98 Capone S., Reyes-Sandoval A., Naddeo M., Siani L., Ammendola V., Rollier CS., Nicosia A., Colloca S., Cortese R., Folgori A., Hill AV.
Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
Vaccine. 2010 Dec 16;29(2):256-65

99 Draper SJ., Biswas S., Spencer AJ., Remarque EJ., Capone S., Naddeo M., Dicks MD., Faber BW., de Cassan SC., Folgori A., Nicosia A., Gilbert SC., Hill AV.
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
J Immunol. 2010 Dec 15;185(12):7583-95

100 Sheehy SH., Duncan CJ., Elias SC., Collins KA., Ewer KJ., Spencer AJ., Williams AR., Halstead FD., Moretz SE., Miura K., Epp C., Dicks MD., Poulton ID., Lawrie AM., Berrie E., Moyle S., Long CA., Colloca S., Cortese R., Gilbert SC., Nicosia A., Hill AV., Draper SJ.
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Mol Ther. 2011 Dec;19(12):2269-76

101 Sheehy S., Duncan C., Anagnostou N., Elias S., Halstead F., Collins K., Ewer K., Edwards N., Douglas A., Gantlett K., Lawrie A., Berrie E., Moyles S., Long C., Sinden R., Blagborough A., Murphy J., Nicosia A., Hill A., Draper S.
Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1
J Infect **63**(6):492-493 (2011)

102 Sheehy SH., Duncan CJ., Elias SC., Collins KA., Ewer KJ., Spencer AJ., Williams AR., Halstead FD., Moretz SE., Miura K., Epp C., Dicks MD., Poulton ID., Lawrie AM., Berrie E., Moyle S., Long CA., Colloca S., Cortese R., Gilbert SC., Nicosia A., Hill AV., Draper SJ.

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Mol Ther. 2011 Dec;19(12):2269-76

103 Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., Meyer J., Huddart R., Smith K., Townsend R., Brown A., Antrobus R., Ammendola V., Naddeo M., O'Hara G., Willberg C., Harrison A., Grazioli F., Esposito ML., Siani L., Traboni C., Oo Y., Adams D., Hill A., Colloca S., Nicosia A., Cortese R., Klenerman P.
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.
Sci Transl Med. 2012 Jan 4;4(115):115ra1

104 Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., Siani L., Naddeo M., Grazioli F., Esposito ML., Ambrosio M., Sparacino A., Bartiromo M., Meola A., Smith K., Kurioka A., O'Hara GA., Ewer KJ., Anagnostou N., Bliss C., Hill AV., Traboni C., Klenerman P., Cortese R., Nicosia A.
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species
Sci Transl Med. 2012 Jan 4;4(115):115ra2

105 Rosario M., Borthwick N., Stewart-Jones GB., Mbewe-Mvula A., Bridgeman A., Colloca S., Montefiori D., McMichael AJ., Nicosia A., Quakkelaar ED., Drijfhout JW., Melief CJ., Hanke T.
Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
AIDS. 2012 Jan 28;26(3):275-84

106 Meuleman P., Catanese MT., Verhoye L., Desombere I., Farhoudi A., Jones CT., Sheahan T., Grzyb K., Cortese R., Rice CM., Leroux-Roels G., Nicosia A.
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
Hepatology. 2012 Feb;55(2):364-72

107 Knudsen ML., Mbewe-Mvula A., Rosario M., Johansson DX., Kakoulidou M., Bridgeman A., Reyes-Sandoval A., Nicosia A., Ljungberg K., Hanke T., Liljeström P.
Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.
J Virol. 2012 Apr;86(8):4082-90

108 Sheehy SH., Duncan CJ., Elias SC., Biswas S., Collins KA., O'Hara GA., Halstead FD., Ewer KJ., Mahunqu T., Spencer AJ., Miura K., Poulton ID., Dicks MD., Edwards NJ., Berrie E., Moyle S., Colloca S., Cortese R., Gantlett K., Long CA., Lawrie AM., Gilbert SC., Doherty T., Nicosia A., Hill AV., Draper SJ.
Phase la clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
PLoS One. 2012;7(2):e31208. Epub 2012 Feb 21

109 O'Hara GA., Duncan CJ., Ewer KJ., Collins KA., Elias SC., Halstead FD., Goodman AL., Edwards NJ., Reyes-Sandoval A., Bird P., Rowland R., Sheehy SH., Poulton ID., Hutchings C., Todryk S., Andrews L., Folgori A., Berrie E., Moyle S., Nicosia A., Colloca S., Cortese R., Siani L., Lawrie AM., Gilbert SC., Hill AV.
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector.
J Infect Dis. 2012 Mar;205(5):772-81

110 Abdelwahab SF., Zakaria Z., Sobhy M., Rewisha E., Mahmoud MA., Amer MA, Del Sorbo M., Capone S., Nicosia A., Folgori A., Hashem M., El-Kamari SS.
Hepatitis C Virus-multispecific T-Cell Responses without viremia or seroconversion among Egyptian Health Care Workers at High Risk of Infection.

Clin Vaccine Immunol. 2012 May;19(5):780-6

111 Lacek K., Vercauteren K., Grzyb K., Naddeo M., Verhoye L., Slowikoswki MP., Fafi-Kremer S., Patel AH., Baumert TF., Folgori A., Leroux-Roels G., Cortese R., Meuleman P., Nicosia A.
Novel Human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.
J Hepatology. 2012 Jul;57(1);17-23

112 Sheehy SH., Duncan CJ., Elias SC., Choudhary P., Biswas S., Halstead FD., Collins KA., Edwards NJ., Douglas AD., Anagnostou NA., Ewer KJ., Havelock T., Mahungu T., Bliss CM., Miura K., Poulton ID., Lillie PJ., Antrobus RD., Berrie E., Moyle S., Gantlett K., Colloca S., Cortese R., Long CA., Sinden RE., Gilbert SC., Lawrie AM,. Doherty T., Faust SN., Nicosia A., Hill AV., Draper SJ.
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
Mol Ther. 2012 Dec;20(12):2355-68

113 Park SH., Shin EC., Capone S., Caggiari L., De Re V., Nicosia A., Folgori A., Rehermann B.
Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.
Gastroenterology. 2012 Oct;143(4):1048-60.e4

114 Quinn KM., Da Costa A., Yamamoto A., Berry D., Lindsay RW., Darrah PA., Wang L., Cheng C., Kong WP., Gall JG., Nicosia A., Folgori A., Colloca S., Cortese R., Gostick E., Price DA., Gomez CE., Esteban M., Wyatt LS., Moss B., Morgan C., Roederer M., Bailer RT., Nabel GJ., Koup RA., Seder RA.
Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization.
J Immunol. 2013 Mar 15;190(6):2720-35

115 Ogwang C., Afolabi M., Kimani D., Jankey Jagne Y., Sheeby S.H., Bliss CM., Duncan CJA. Collins KA., Garcia Knight MA.m Kimani E., Anagnostou NA., Berrie E., Moyle S., Gilbert SC., Spencer AJ., Soipei P., Mueller J., Okebe J., Colloca S., Cortese R., Viebig NK., Roberts R., Gantlett K., Lawrie AM., Nicosia A., Imoukhuede EB., Bejon P., Urban BC., Flanagan KL., Ewer KJ., Chilengi R., Hill AVS., Bojang K.
Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAdAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults.
Plos One, 8(3) e57726 (2013)

116 Vitelli A., Quiron MR., Lo CY., Misplon JA., Grabowska AK., Pierantoni A., Ammendola V., Price GE., Soboleski MR., Cortese R., Colloca S., Nicosia A., Epstein SL.
Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan Paniscus.
PLos One, 2013;8(3):e55435

117 Capone S., D'Alise AM., Ammendola V., Colloca S., Cortese R., Nicosia A., Folgori A.
Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
Expert Rev Vaccines. 2013 Apr;12(4):379-93. doi: 10.1586/erv.13.15

118 Ondondo B., Brennan C., Nicosia A., Crome SJ., Hanke T.
Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, CHAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
Vaccine, 2013 Nov 12;31(47):5594-601

119 Ewer KJ., O'Hara GA., Duncan CJ., Collins KA., Sheehy Sh., Reyes-Sandoval A., Goodman AL., Edwards NJ., Elias SC.,Halstead FD., Longley RJ., Rowland R., Poulton ID., Draper SJ.,

Blagborough AM., Berrie E., Moyle S., Williams N., Siani L., Folgori A., Colloca S., Sinden RE, Lawrie AM, Cortese R., Gilbert SC., Nicosia A., Hill AV.
Protective CD8-T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.
Nat Commun. 2013;4:2836

120 Borthwick N., Ahmed T., Ondondo B., Hayes P-., Rose A., Ebrahimsa U., Hayton EJ., Black A., Bridgeman A., Rosario M., Hill Av., Berrie E., Moyle S., Frahm N., Cox J., Colloca S., Nicosia A., Gilmour J., McMichael AJ., Dorrell L., Hanke T.
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1-
Mol Ther. 2014 Feb;22(2):464-75

121 Prentoe J., Serre SB., Ramirez S., Nicosia A., Gottwein JM, Bukh J.
Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.
J Virol. 2014 Feb;88(3):1725-39

122 Capone S., Naddeo M., D'Alise AM., Abbate A., Grazioli F., Del Gaudio A., Del Sorbo M., Esposito ML., Ammendola V., Perretta G., Taglioni A., Colloca S., Nicosia A., Cortese R., Folgori A.
Fusion of HCV Nonstructural Antigen to MHC Class II-associated Invariant Chain Enhances T-cell Responses Induced by Vectored Vaccines in Nonhuman Primates.
Mol. Ther. 2014 May;22(5):1039-47

123 Chmielewska AM., Naddeo M., Capone S., Ammendola V., Hu K., Meredith L., Verhoye L., Rychlowska M., Rappuoli R., Ulmer JB., Colloca S., Nicosia A., Cortese R., Leroux-Roels G., Balfe P., Bienkowska-Szewczyk K., Meuleman P., McKeating JA., Folgori A.
Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
J Virol. 2014 May;88(10):5502-10

124 Paris R., Kuschner RA., Binn L., Thomas SJ., Colloca S., Nicosia A., Cortese R., Bailer RT., Sullivan N., Koup RA.
Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
Clin Vaccine Immunol. 2014 May;21(5):783-6

125 Spencer AJ., Cottingham MG., Jenks JA., Longley RJ., Capone S., Colloca S., Folgori A., Cortese R., Nicosia A., Bregu M., Hill AV.
Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain.
PLoS One. 2014 Jun 19;9(6):e100538

126 Mathiesen CK., Jensen TB., Prentoe J., Krarup H., Nicosia A., Law M., Bukh J., Gottwein JM.
Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.
Virology. 2014 Jun;458-459:190-208

127 Hodgson SH., Choudhary P., Elias SC., Milne KH., Rampling TW., Biswas S., Poulton ID., Miura K., Douglas AD., Alanine DG., Illingworth JJ., de Cassan SC., Zhu D., Nicosia A., Long CA., Moyle S., Berrie E., Lawrie AM., Wu Y., Ellis RD., Hill AV., Draper SJ.
Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial.
Mol Ther. 2014 Aug 26.

128 Stanley DA., Honko AN., Asiedu C., Trefry JC., Lau-Kilby AW., Johnson JC., Hensley L., Ammendola V., Abbate A., Grazioli F., Foulds KE., Cheng C., Wang L., Donaldson MM., Colloca S., Folgori A., Roederer M., Nabel GJ., Mascola J., Nicosia A., Cortese R., Koup RA., Sullivan NJ.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.
Nat Med. 2014 Oct;20(10):1126-9

129 Hodgson SH., Ewer KJ., Bliss CM., Edwards NJ., Rampling T., Anagnostou NA., de Barra E., Havelock T., Bowyer G., Poulton ID., de Cassan S., Illingworth JJ., Douglas AD., Mange PB., Collins KA., Roberts R., Gerry S., Berrie E., Moyle S., Colloca S., Cortese R., Sinden RE., Gilbert SC., Bejon P., Lawrie AM., Nicosia A., Faust SN., Hill AV.
Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing CS & ME-TRAP Against Controlled Human Malaria Infection in Malaria Naïve Individuals.
J Infect Dis. 2014 Oct 21. pii: jiu579

130 Lacek K., Urbanowicz RA., Troise F., De Lorenzo C., Severino V., Di Maro A., Tarr AW., Ferrara F., Ploss A., Temperton N., Ball JK., Nicosia A., Cortese R., Pessi A.
Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation.
J Biol Chem. 2014 Oct 23. pii: jbc.M114.591826

131 Bankwitz D., Vieyres G., Hueging K., Bitzegeio J., Doepke M., Chhatwal P., Haid S., Catanese MT., Zeisel MB., Nicosia A, Baumert TF., Kaderali L., Pietschmann T.
Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
J Virol. 2014 Nov 1;88(21):12644-55

132 Kimani D., Jagne YJ., Cox M., Kimani E., Bliss CM., Gitau E., Ogwang C., Afolabi MO., Bowyer G., Collins KA., Edwards N., Hodgson SH., Duncan CJ., Spencer AJ., Knight MG., Drammeh A., Anagnostou NA., Berrie E., Moyle S., Gilbert SC., Soipei P., Okebe J., Colloca S., Cortese R., Viebig NK., Roberts R., Lawrie AM., Nicosia A., Imoukhuede EB., Bejon P., Chilengi R., Bojang K., Flanagan KL., Hill AV., Urban BC., Ewer KJ.
Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations.
Mol Ther. 2014 Nov;22(11):1992-2003

133 Vercauteren K., Van Den Eede N., Mesalam AA., Belouzard S., Catanese MT., Bankwitz D., Wong-Staal F., Cortese R., Dubuisson J., Rice CM., Pietschmann T., Leroux-Roels G., Nicosia A., Meuleman P.
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Hepatology. 2014 Nov;60(5):1508-18

134 Callendret B., Eccleston HB., Hall S., Satterfield W., Capone S., Folgori A., Cortese R., Nicosia A., Walker CM.
T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.
Hepatology. 2014 Nov;60(5):1531-40

135 Swadling L., Capone S., Antrobus RD., Brown A., Richardson R., Newell EW., Halliday J., Kelly C., Bowen D., Fergusson J., Kurioka A., Ammendola V., Del Sorbo M., Grazioli F., Esposito ML., Siani L., Traboni C., Hill A., Colloca S., Davis M., Nicosia A., Cortese R., Folgori A., Klenerman P., Barnes E.
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Sci Transl Med. 2014 Nov 5;6(261):261ra153

136 Ledgerwood JE., DeZure AD., Stanley DA., Novik L., Enama ME., Berkowitz NM., Hu Z., Joshi G., Ploquin A., Sitar S., Gordon IJ., Plummer SA., Holman LA., Hendel CS., Yamshchikov G., Roman F., Nicosia A., Colloca S., Cortese R., Bailer RT., Schwartz RM., Roederer M., Mascola JR., Koup RA., Sullivan NJ., Graham BS.; the VRC 207 Study Team.

Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report.
N Engl J Med. 2014 Nov 2

137 de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie AM, Gilbert SC, Nicosia A, McConkey SJ, Hill AV.
A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
PLoS One. 2014 Dec 18;9(12):e115161. doi: 10.1371/journal.pone.0115161. eCollection 2014.

138 Foquet L, Hermsen CC, Verhoye L, van Gemert GJ, Cortese R, Nicosia A, Sauerwein RW, Leroux-Roels G, Meuleman P.
Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model.
J Antimicrob Chemother. 2015 Feb 4. pii: dkv019.

139 Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, Lynn GM, Darrah PA, Lindsay RW, Wang L, Cheng C, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gall JG, Roederer M, Aderem A, Seder RA.
Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.
J Clin Invest. 2015 Mar 2; 125(3):1129-46. doi: 10.1172/JCI78280. Epub 2015 Feb 2.

140 Hodgson S.H., Ewer K. J. Bliss C. M., Edwards N. J., Rampling T., Anagnostou N. A., de Barra E., Havelock T., Bowyer G., Poulton I. D., de Cassan S., Longley R., Illingworth J. J., Douglas A. D., Mange P. B., Collins K. A., Roberts R., Gerry S., Berrie E., Moyle S., Colloca S., Cortese R., Sinden R. E., Gilbert S. C., Bejon P., Lawrie A. M., Nicosia A, Faust S. N., Hill A. V.
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
The Journal of infectious diseases, 2015 Apr 1; 211(7):1076-86. doi: 10.1093/infdis/jiu579.

141 Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, S Hill AV, Bejon P; MVVC group.
Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.
Sci Transl Med. 2015 May 6; 7(286):286re5. doi: 10.1126/scitranslmed.aaa2373.

142 Pierantoni A., Esposito M. L., Ammendola V., Napolitano F., Grazioli F., Abbate A., Del Sorbo M., Siani L., D'Alise A. M., Taglioni A., Perretta G., Siccardi A., Soprana E., Panigada M., Thom M., Scarselli E., Folgori A., Colloca S., Taylor G., Cortese R., Nicosia A., Capone S., Vitelli A.
Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.
Molecular therapy. Methods & clinical development, 2015 May 20; 2:15018. doi: 10.1038/mtm.2015.18.

143 Kapulu M.C., Da D. F., Miura K., Li, Y., Blagborough A. M., Churcher T. S., Nikolaeva D., Williams A. R., Goodman A. L., Sangare I., Turner A. V., Cottingham M. G., Nicosia A., Straschil U., Tsuboi T., Gilbert S. C., Long C. A., Sinden R. E., Draper S. J., Hill, A. V., Cohuet A., Biswas S.
Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
Scientific reports, 2015 Jun 11; 5:11193. doi: 10.1038/srep11193.

144 Green C.A., Scarselli E., Sande C. J, Thompson A. J., de Lara C. M., Taylor K. S., Haworth K., Del Sorbo M., Angus B., Siani L., Di Marco S., Traboni C., Folgori A., Colloca S., Capone S., Vitelli A., Cortese R., Klenerman P., Nicosia A., Pollard A. J.
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Science translational medicine, 2015 Aug 12; 7(300):300ra126. doi: 10.1126/scitranslmed.aac5745.

145 Taylor G., Thom M., Capone S., Pierantoni A., Guzman E., Herbert R., Scarselli E., Napolitano F., Giuliani A., Folgori A., Colloca S., Cortese R., Nicosia A., Vitelli A.
Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
Science translational medicine, 2015 Aug 12; 7(300):300ra127. doi: 10.1126/scitranslmed.aac5757.

146 Vercauteren K., Brown R. J., Mesalam A. A., Doerrbecker J., Bhuju S., Geffers R., Van Den Eede N., McClure C. P., Troise F., Verhoye L., Baumert T., Farhoudi A., Cortese R., Ball J. K., Leroux-Roels G., Pietschmann T., Nicosia A., Meuleman P.
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Gut, Aug. 2015. Gut doi: 10.1136/gutjnl-2014-309045

147 Urbanowicz R.A., Lacek K., Lahm A., Bienkowska-Szewczyk K., Ball J. K., Nicosia A., Cortese R., Pessi A.
Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin.
Journal of peptide science: an official publication of the European Peptide Society, 2015 Sep; 21(9):743-9. doi: 10.1002/psc.2802.

148 Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P.
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Gut. 2015 Aug 25. pii: gutjnl-2014-309045. doi: 10.1136/gutjnl-2014-309045.

149 Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese R, Thompson AJ, Sande CS, de Lara C, Klenerman P, Pollard AJ.
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
BMJ Open. 2015 Oct 28; 5(10):e008748. doi: 10.1136/bmjopen-2015-008748.

150 Sasso E, Paciello R, D'Auria F, Riccio G, Froechlich G, Cortese R, Nicosia A, De Lorenzo C, Zambrano N.
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.
Biomed Res Int. 2015; 2015:703213. doi: 10.1155/2015/703213. Epub 2015 Nov 15.

151 Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure PC, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C.
Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb.
J Gen Virol. 2016 Jan;97(1):82-94. doi: 10.1099/jgv.0.000330.

152 Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F,

De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
N Engl J Med. 2016 Apr 28; 374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

153 Callendret B, Eccleston HB, Satterfield W, Capone S, Folgori A, Cortese R, Nicosia A, Walker CM.
Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
Hepatology. 2016 May; 63(5):1442-54. doi: 10.1002/hep.28309. Epub 2015 Dec 18.

154 Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Luisa Esposito M, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.
Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans.
Hepatology. 2016 May; 63(5):1455-70. doi: 10.1002/hep.28294. Epub 2016 Jan 22.

155 Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima SB.
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
Mol Ther. 2016 Jun 28. doi: 10.1038/mt.2016.83.

156 Esposito S, Scarselli E, Lelii M, Scala A, Vitelli A, Capone S, Fornili M, Biganzoli E, Orenti A, Nicosia A, Cortese R, Principi N.
Antibody Response To Respiratory Syncytial Virus Infection In Children <18 Months Old.
Hum Vaccin Immunother. 2016 Jul 2; 12(7):1700-6. doi: 10.1080/21645515.2016.1145847. Epub 2016 Feb 22.

157 Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E.
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.
Vaccines (Basel). 2016 Aug 2;4(3). pii: E27. doi: 10.3390/vaccines4030027.

158 Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, Syll M, Ndaw A, Abiola A, Bliss C, Gomis JF, Petersen I, Ogwang C, Dieye T, Viebig NK, Lawrie AM, Roberts R, Nicosia A, Faye B, Gaye O, Leroy O, Imoukhuede EB, Ewer KJ, Bejon P, Hill AV, Cisse B; MVVC group.
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
PLoS One. 2016 Dec 15;11(12):e0167951. doi: 10.1371/journal.pone.0167951.

159 Vitelli A, Nicosia A.
Virus vs. virus: adenovirus vectored vaccine to defeat respiratory syncytial virus.
Ann Transl Med. 2016 Dec;4(24):489. doi: 10.21037/atm.2016.12.08.

160 Ragonnaud E, Andersson AC, Mariya S, Pedersen AG, Burk RD, Folgori A, Colloca S, Cortese R, Nicosia A, Pamungkas J, Iskandriati D, Holst PJ.
Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix.
J Immunother. 2017 Feb/Mar;40(2):51-61. doi: 10.1097/CJI.0000000000000153.

161 Leoni V, Gatta V, Casiraghi C, Nicosia A, Petrovic B, Campadelli-Fiume G.
A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
J Virol. 2017 Apr 28;91(10). pii: e00067-17. doi: 10.1128/JVI.00067-17. Print 2017 May 15.

162 Xu H, Andersson AM, Ragonnaud E, Boilesen D, Tolver A, Jensen BAH, Blanchard JL, Nicosia A, Folgori A, Colloca S, Cortese R, Thomsen AR, Christensen JP, Veazey RS, Holst PJ.
Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.
EBioMedicine. 2017 Apr;18:204-215. doi: 10.1016/j.ebiom.2017.03.003. Epub 2017 Mar 8.

163 Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ, Poulton ID, Roberts R, Farid R, Jørgensen T, Alanine DG, de Cassan SC, Higgins MK, Otto TD, McCarthy JS, de Jongh WA, Nicosia A, Moyle S, Hill AV, Berrie E, Chitnis CE, Lawrie AM, Draper SJ.
Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.
JCI Insight. 2017 Jun 15;2(12). pii: 93683. doi: 10.1172/jci.insight.93683.

164 Quinn K, Traboni C, Penchala SD, Bouliotis G, Doyle N, Libri V, Khoo S, Ashby D, Weber J, Nicosia A, Cortese R, Pessi A, Winston A.
A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.
Sci Rep. 2017 Aug 25;7(1):9447. doi: 10.1038/s41598-017-09230-0.

165 Vitelli A, Folgori A, Scarselli E, Colloca S, Capone S, Nicosia A.
Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.
Expert Rev Vaccines. 2017 Dec;16(12):1241-1252. doi: 10.1080/14760584.2017.1394842. Epub 2017 Oct 30

166 Spada E, Rezza G, Garbuglia AR, Lombardo FL, Zuccaro O, Menniti Ippolito F, Cupellaro E, Capone S, Capobianchi MR, Nicosia A, Cortese R, Folgori A, Mele A; Collaborative Study Group.
Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.
J Urban Health. 2018 Feb;95(1):99-110. doi: 10.1007/s11524-017-0207-5.

167 Mensah VA, Roetynck S, Kanteh EK, Bowyer G, Ndaw A, Oko F, Bliss CM, Jagne YJ, Cortese R, Nicosia A, Roberts R, D'Alessio F, Leroy O, Faye B, Kampmann B, Cisse B, Bojang K, Gerry S, Viebig NK, Lawrie AM, Clarke E, Imoukhuede EB, Ewer KJ, Hill AVS, Afolabi MO.
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial.
Front Immunol. 2017 Nov 20;8:1551. doi: 10.3389/fimmu.2017.01551. eCollection 2017.

168 Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ.
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Sci Rep. 2018 Feb 21;8(1):3390. doi: 10.1038/s41598-018-21630-4.

169 Sasso E, Latino D, Froechlich G, Succoio M, Passariello M, De Lorenzo C, Nicosia A, Zambrano N.
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells.
MAbs. 2018 Apr 16:1-8. doi: 10.1080/19420862.2018.1463945.

170 Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.
Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome
JAMA Oncol. 2018 Apr 16. doi: 10.1001/jamaoncol.2018.1482.

171 Sasso E, D'Avino C, Passariello M, D'Alise AM, Siciliano D, Esposito ML, Froechlich G, Cortese R, Scarselli E, Zambrano N, Nicosia A, De Lorenzo C.
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.
MAbs. 2018 Oct; 10(7):1060-1072. doi: 10.1080/19420862.2018.1496772. Epub 2018 Aug 1.

172 Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, Silva-Reyes L, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Hutchings CL, Cargill T, Angus B, Klenerman P, Pollard AJ.
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
J Infect. 2019 Feb 8. pii: S0163-4453(19)30038-6. doi: 10.1016/j.jinf.2019.02.003.

173 A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L.
Front Immunol. 2019 Jan 18;9:3175. doi: 10.3389/fimmu.2018.03175. eCollection 2018.

174 Antigen-specific CD8 T cells in cell cycle circulate in the blood after vaccination.
Simonetti S, Natalini A, Folgori A, Capone S, Nicosia A, Santoni A, Di Rosa F.
Scand J Immunol. 2019 Feb;89(2):e12735. doi: 10.1111/sji.12735. Epub 2019 Jan 15.

LISTA DELLE PATENTI

1) Patent # EPO232229, “Cloning and expression of bordetella pertussis toxin-encoding DNA”, inventors: Rino Rappuoli, Alfredo Nicosia, Maria Beatrice Aricò
2) Patent # US 6350612, “Isolation and expression of DNA sequence encoding the five subunits of Bordetella pertussis toxin”, inventors: Rino Rappuoli, Alfredo Nicosia, Maria Beatrice Aricò
3) Patent # US 5427788, “Pertussis toxin and use in vaccines”, inventors: Rino Rappuoli, Alfredo Nicosia, Maria Beatrice Aricò
4) Patent # WO/1994/026886, “Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable”, inventors: Franco Felici, Alessandra Luzzago, Alfredo Nicosia, Paolo Monaci, Riccardo Cortese
5) Patent # WO/1999/060132, “Mimotopes of hypervariable region 1 of the E2 glycoprotein of HCV and uses thereof”, inventors: Alfredo Nicosia, Armin Lahm, Anna Tramontano, Riccardo Cortese
6) Patent # WO/2003/031588, “Hepatitis C Virus Vaccine”, inventors: Emilo A. Emini, David Kaslow, Andrew J. Bett, John Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca.
7) Patent # WO 2005/053670, “Ppar Agonists for the treatment of HCV infection”, inventors: Riccardo Cortese, Alfredo Nicosia, Alessandra Vitelli

8) Patent # WO/2005/071093, “Chimpanzee Adenovirus Vaccine Carriers”, inventors: Agostino Cirillo, Stefano Colloca, Ercole Bruno Bruni, Annalisa Meola, Alfredo Nicosia, Elisabetta Sporeno
9) Patent # WO/2006/133911, “Hepatitis C Virus Nucleic Acid Vaccine”, inventors: Armin Lahm, Stefano Colloca, Antonella Folgori, Alfredo Nicosia
10) Patent # WO/2006/005465, “Antigen Binding Proteins Directed Against Scavenger Receptor B1 that Inhibit HCV Replication”, Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli
11) Patent # WO/2009/146902,“A Vaccine for the prevention and therapy of HCV infections”, inventors: Riccardo Cortese, Alfredo Nicosia
12) Patent # WO/2010/085984, “Simian Adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof”, inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
13) Patent # WO/2011/086001, “Antibodies for the treatment of HCV”, inventors: Riccardo Cortese, Alfredo Nicosia
14) Patent # WO/2012/003995, “Lipid-conjugated Antibodies”, inventors: Antonello Pessi, Alfredo Nicosia, Riccardo Cortese
15) Patent # WO/2012/089833, “Expression Systems”, inventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
16) Patent # WO/2012/089231, “Paramyxovirus Vaccine”, inventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
17) Patent # PCT/IB2014/059802, “Improved Poxviral Vaccines”, inventors: Antonella Folgori, Riccardo Cortese, Alfredo Nicosia, Stefano Colloca.
18) Patent # WO/2011/130627A3, “Chimpanzee Adenoviral Vector-based Filovirus Vaccines”, inventors: Nancy Sullivan, Gary J. Nabel, Asiedu Clement, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca.
19) Patent # WO/2014/005643A1 “Novel Prime-boosting Regimens Involving Immunogenic Polypeptides Encoded by Polynucleotides”, inventors: Alfredo Nicosia, Riccardo Cortese, Alessandra Vitelli.
20) Patent # WO/2019/012082 A1 “A Universal Vaccine Based on Shared Tumor Neoantigens for Prevention and Treatment of Micro Satellite Instable (MSI) Cancers”, inventors: Alfredo Nicosia, Elisa Scarselli, Guido Leoni, Armin Lahm.
21) Patent # WO/2019/008111 A1 “Non Human Great Apes Adenovirus Nucleic Acid And Amino Acid-Sequences, Vectors Containing Same, And Uses Thereof”, inventors: Alfredo Nicosia, Stefano Colloca, Armin Lahm.